Handelsavisen
prelaunch
Companies ›Healthcare ›BCDA
BC
BCDA — Nasdaq Biotechnology & Medical Research

BioCardia, Inc.

$0,82
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
LatestBCDA projects $40B-$70B investment for Pax Silica tech hub in New Clark City
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
8,9M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
211,9 %
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
1,7k
Day range
$0,85–$0,91
Prev close
$0,91
Open
$0,91
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About

BioCardia, Inc. develops cell therapy systems for heart failure, generating no revenue while incurring significant R&D and SG&A expenses to advance clinical trials.

Business. BioCardia, Inc. (BCDA) is a pharmaceutical company operating within the Healthcare sector. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY2 analysts
2 buy0 hold0 sell
Avg 12m price target15,50

Analyst recommendations

2 analysts · consensus Buy
Buy2
Hold0
Sell0
12-month price target
15,50
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
2 analysts · indicative
Ownership→
Geode Capital Management, L.L.C.
largest disclosed fund holder
Profitability→
211,9 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

2
  • MARKETSBCDA projects $40B-$70B investment for Pax Silica tech hub in New Clark City2026-07-23
  • MARKETSSubic Bay Port designated primary gateway for Pax Silica semiconductor logistics2026-07-20

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to BCDA. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · 2026-07-20

    Composite-score breakdown

    Synthesis

    Business

    BioCardia, Inc. (BCDA) is a pharmaceutical company operating within the Healthcare sector. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    BioCardia operates with a negative equity position of -$1.07 million and total liabilities of $2.78 million against total assets of $1.71 million as of Q1 2026. The current ratio stands at 0.41, indicating current liabilities exceed current assets, while cash and equivalents total $0.95 million. Operating cash flow is negative $1.66 million, and free cash flow is negative $1.66 million, reflecting a heavy cash burn rate. The company has an accumulated deficit of approximately $170.6 million, raising substantial doubt about its ability to continue as a going concern beyond one year.

    Profitability metrics are distorted by the negative equity base, with a reported return on equity of 211.91% and return on assets of -131.95%. The company reported an operating loss of -$2.27 million and a net loss of -$2.26 million for Q1 2026. As a pre-revenue clinical-stage biotech, traditional profitability comparisons are not applicable; the primary economic driver is the successful progression of its cell therapy programs toward regulatory approval and commercialization.

    Key takeaways
    • BioCardia faces substantial going-concern risks with negative equity of -$1.07M and a current ratio of 0.41.
    • The company burned $1.66M in cash during Q1 2026, with no revenue to offset operating losses.
    • Stock price fell below $1.00 in July 2026, triggering Nasdaq continued-listing deficiency warnings.
    • Dilution risk is medium due to active ATM facilities and recent equity financings in 2024-2025.
    • Analyst price targets average $15.50, suggesting high market expectations for clinical success despite current financial distress.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-03-31
    Q4 2025 · Quarter highlights

    Operating income -$2.3M.

    Revenue—
    Operating income-$2.3M
    Net income-$2.3M
    Free cash flow-$1.7M
    EPS—
    Operating cash flow-$1.7M
    Financials
    Income statement
    Revenue—
    Gross profit—
    Operating income-$2.3M
    Net income-$2.3M
    Balance sheet
    Total assets$1.7M
    Total liabilities$2.8M
    Total equity-$1.1M
    Cash & equivalents$951.0k
    Long-term debt—
    Cash flow
    Operating cash flow-$1.7M
    CapEx$3.0k
    Free cash flow-$1.7M
    SBC$113.0k
    Highlights
    • ▍Operating income -$2.3M

    Valuation FY

    Market price
    $0,82
    Market cap
    $9.9M
    Enterprise valueⓘ
    $8.9M
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    -$1.1M
    Net cashⓘ
    $951.0k
    Current ratioⓘ
    0.4
    Debt / equityⓘ
    —
    ROAⓘ
    -1.3%
    ROEⓘ
    2.1%
    Cash conversionⓘ
    73.0%
    CapEx / revenueⓘ
    —
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    -1.2%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 41 %
    EPS
    Consensus EPS
    -0,68
    Predicted surprise
    -0,08
    Beat probability
    41 %
    Analysts
    2
    Other metrics
    Revenue
    —
    no estimate
    Segment revenue
    —
    no estimate
    Margin
    —
    no estimate
    Segment margin
    —
    no estimate
    revision ratio -0,08 · as of 2026-07-12 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPS—no estimate—no estimate-0,68
    Revenue—no estimate—no estimate0 USD
    Operating income—no estimate—no estimate-9,1M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution2 analysts
    Strong buy0
    Buy2
    Hold0
    Sell0
    Strong sell0
    12-month price target$15,50 · Median $15,50
    Low $6,00High $25,00
    Operating income · consensus-9,1M USD
    EPS surprise
    −80,9 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$6,00
    Mean$15,50
    Median$15,50
    High$25,00
    Spot$0,82
    +1783.1 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskMedium
    Liquidity riskHigh
    Filing-based flags
    • Current liabilities exceed current assets.
    • Filings reference going-concern or substantial-doubt language.
    • Source documents mention dilution or offering risk.

    Benchmarks vs cohort

    ROE211,9 %Best in class
    D/E-0,00Above median
    Cash Conv0,73Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 866 400 sh9 grants9 insiders
    • McClung DavidChief Financial Officer · Stock Option (right to buy) → Common stockAcquired 20 000 @ $1,37grant · 2025-12-08
    • STERTZER SIMON HDirector · Stock Option (right to buy) → Common StockAcquired 12 000 @ $1,37grant · 2025-12-08
    • Altman PeterDirector, President and CEO · Stock Option (right to buy) → Common stockAcquired 20 000 @ $1,37grant · 2025-12-08
    • Facteau BillDirector · Stock Option (right to buy) → Common StockAcquired 12 000 @ $1,37grant · 2025-12-08
    • MOYES JAY MDirector · Stock Option (right to buy) → Common StockAcquired 12 000 @ $1,37grant · 2025-12-08
    • Allen Jim L.Director · Stock Option (right to buy) → Common StockAcquired 12 000 @ $1,37grant · 2025-12-08
    • GILLIS EDWARD MSenior Vice President, Devices · Stock Option (right to buy) → Common stockAcquired 20 000 @ $1,37grant · 2025-12-08
    • Blank Andrew ScottDirector · Stock Option (right to buy) → Common StockAcquired 12 000 @ $1,37grant · 2025-12-08
    • Slosman MarvinDirector · Stock Option (right to buy) → Common StockAcquired 12 000 @ $1,37grant · 2025-12-08
    • STERTZER SIMON HDirector · Warrant (right to buy) → Common StockAcquired 398 400 @ $1,25purchase · 2025-09-19
    • Blank Andrew ScottDirector · Warrant (right to buy) → Common StockAcquired 288 000 @ $1,25purchase · 2025-09-19
    • Altman PeterDirector, President and CEO · Warrant (right to buy) → Common StockAcquired 48 000 @ $1,25purchase · 2025-09-19

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Regulatory filings
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    • Reference data
    How metrics are computed
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Market Cap
      market_price * shares_outstanding_diluted
    • Return On Assets
      net_income / total_assets
    • Enterprise Value
      market_cap - net_cash
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    Source documents
    • BioCardia, Inc. company facts · 2026-07-12
    • BioCardia, Inc. 10-Q 2026-05-15 · 2026-07-12
    • BioCardia, Inc. 10-K 2026-03-24 · 2026-07-12
    • BioCardia, Inc. 10-Q 2025-11-12 · 2026-07-12
    • BioCardia, Inc. 10-Q 2025-08-11 · 2026-07-12
    • ha_price_listing fired on BCDA · 2026-07-12
    • BioCardia Inc Market data — analyst estimates · 2026-07-12

    Ownership & reference

    Top holders

    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$0M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Leadership

    • Peter AltmanPresident, Chief Executive Officer, Director

    Insider activity

    Net buying22 buys · 0 sellsnet $1,1M5 insiders · last 365d
    • STERTZER SIMON HDirector · Common StockBought 39 000 @ $1,00$39K · 2026-06-23
    • STERTZER SIMON HDirector · Common StockBought 70 200 @ $0,92$65K · 2026-06-22
    • Altman PeterDirector, President and CEO · Common StockBought 800 @ $0,96$768 · 2026-06-18
    • Altman PeterDirector, President and CEO · Common StockBought 1 500 @ $0,85$1K · 2026-06-17
    • Altman PeterDirector, President and CEO · Common StockBought 5 000 @ $0,85$4K · 2026-06-09
    • Altman PeterDirector, President and CEO · Common StockBought 1 500 @ $0,92$1K · 2026-05-20
    • Altman PeterDirector, President and CEO · Common StockBought 200 @ $0,95$190 · 2026-05-19
    • Altman PeterDirector, President and CEO · Common StockBought 5 700 @ $0,92$5K · 2026-05-18
    • Altman PeterDirector, President and CEO · Common StockBought 5 100 @ $1,02$5K · 2026-05-15
    • Altman PeterDirector, President and CEO · Common StockBought 5 000 @ $1,11$6K · 2026-04-29
    • Altman PeterDirector, President and CEO · Common StockBought 400 @ $1,23$492 · 2026-04-21
    • Altman PeterDirector, President and CEO · Common StockBought 600 @ $1,23$738 · 2026-04-20
    • Altman PeterDirector, President and CEO · Common StockBought 300 @ $1,22$366 · 2026-03-25
    • Altman PeterDirector, President and CEO · Common StockBought 600 @ $1,24$744 · 2026-03-24
    • Altman PeterDirector, President and CEO · Common StockBought 5 000 @ $1,13$6K · 2026-02-04
    • Altman PeterDirector, President and CEO · Common StockBought 300 @ $1,34$402 · 2026-01-21
    • Altman PeterDirector, President and CEO · Common StockBought 600 @ $1,32$792 · 2026-01-20
    • Altman PeterDirector, President and CEO · Common StockBought 900 @ $1,30$1K · 2025-12-17
    • Altman PeterDirector, President and CEO · Common StockBought 200 @ $1,37$274 · 2025-12-16
    • Altman PeterDirector, President and CEO · Common StockOther 56 484 @ $1,37$77K · 2025-12-08
    • Altman PeterDirector, President and CEO · Common StockOther 106 588 @ $1,37$146K · 2025-12-08
    • GILLIS EDWARD MSenior Vice President, Devices · Common StockOther 15 172 @ $1,37$21K · 2025-12-08
    • GILLIS EDWARD MSenior Vice President, Devices · Common StockOther 38 078 @ $1,37$52K · 2025-12-08
    • McClung DavidChief Financial Officer · Common StockOther 29 339 @ $1,37$40K · 2025-12-08
    • McClung DavidChief Financial Officer · Common StockOther 58 276 @ $1,37$80K · 2025-12-08

    Short positioning

    1.3Mshares short+261.2% vs prior
    2.63days to cover
    51.1%short of daily vol
    307fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    BCDACanonical
    Nasdaq · USD

    Intel & risk

    PredictorBeat prob41 %Surprise-0,08Full forecast →
    peak dispatch · 2026-07-20
    OSINT findings
    Dilution riskMedium
    Liquidity riskHigh
    Current liabilities exceed current assets.
    Filings reference going-concern or substantial-doubt language.
    Source documents mention dilution or offering risk.

    Evidence & claims

    From filings & derived data
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): -8.4%Derived (calculated)
    • Return on equity (FY 2025-12-31): -919.3%Derived (calculated)
    • Return on assets (FY 2025-12-31): -241.1%Derived (calculated)
    • Current ratio (FY 2025-12-31): 1.12xDerived (calculated)
    • Debt-to-equity (FY 2025-12-31): 2.81xDerived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): 16.7%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 5.3%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -3.5%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 5.7%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -3.5%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): 13.1%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 6.9%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -12.8%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 57.6%Derived (calculated)
    • Shareholders' equity (annual): USD 895KSEC XBRL filing
    • Capex (annual): USD 7KSEC XBRL filing
    • R&D expense (annual): USD 4.96MSEC XBRL filing
    • EPS (basic) (annual): USD-PER-SHARES -1SEC XBRL filing
    • Operating cash flow (annual): USD -7.44MSEC XBRL filing
    • Operating income (annual): USD -8.28MSEC XBRL filing
    • Shares outstanding (annual): 10.76MSEC XBRL filing
    • Current liabilities (annual): USD 2.43MSEC XBRL filing
    • Current assets (annual): USD 2.73MSEC XBRL filing
    • Total liabilities (annual): USD 2.52MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-07-08 21:47 UTCEVENTHa Price Listing BCDA price below 1 ($0.9652) — US continued-listing minimum-bid threshold
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-23 00:00 UTCINSIDER5 insider transactions — 2026-06 · net buy $110k
    2026-06-23INSIDERSTERTZER SIMON H bought 39.0k sh — Director ~$39k
    2026-06-22INSIDERSTERTZER SIMON H bought 70.2k sh — Director ~$65k
    2026-06-18FILINGFORM 8-K →
    2026-06-18INSIDERAltman Peter bought 800 sh — Director, President and CEO ~$1k
    2026-06-17INSIDERAltman Peter bought 1.5k sh — Director, President and CEO ~$1k
    2026-06-12FILINGFORM 8-K →
    2026-06-09INSIDERAltman Peter bought 5.0k sh — Director, President and CEO ~$4k
    2026-06-08FILINGFORM 8-K →
    2026-06-05FILINGFORM 8-K →
    2026-05-28FILINGFORM 8-K →
    2026-05-21FILINGFORM 8-K →
    2026-05-20 00:00 UTCINSIDER4 insider transactions — 2026-05
    2026-05-20INSIDERAltman Peter bought 1.5k sh — Director, President and CEO ~$1k
    2026-05-19INSIDERAltman Peter bought 200 sh — Director, President and CEO ~$0k
    2026-05-18INSIDERAltman Peter bought 5.7k sh — Director, President and CEO ~$5k
    2026-05-15FILINGFORM 8-K →
    2026-05-15FILINGFORM 10-Q →
    2026-05-15INSIDERAltman Peter bought 5.1k sh — Director, President and CEO ~$5k
    2026-05-08FILINGFORM 8-K →
    2026-04-29 00:00 UTCINSIDER3 insider transactions — 2026-04
    2026-04-29INSIDERAltman Peter bought 5.0k sh — Director, President and CEO ~$6k
    2026-04-28FILINGFORM 8-K →
    2026-04-21INSIDERAltman Peter bought 400 sh — Director, President and CEO ~$0k
    2026-04-20FILINGFORM 8-K →
    2026-04-20INSIDERAltman Peter bought 600 sh — Director, President and CEO ~$1k
    2026-04-15FILINGFORM 8-K →
    2026-03-31EARNINGSQuarterly results — Q4 2025 Net USD -2.3M
    2026-03-25 00:00 UTCINSIDER2 insider transactions — 2026-03
    2026-03-25INSIDERAltman Peter bought 300 sh — Director, President and CEO ~$0k
    2026-03-24INSIDERAltman Peter bought 600 sh — Director, President and CEO ~$1k
    2026-02-04 00:00 UTCINSIDER1 insider transaction — 2026-02
    2026-02-04INSIDERAltman Peter bought 5.0k sh — Director, President and CEO ~$6k
    2026-01-21 00:00 UTCINSIDER2 insider transactions — 2026-01
    2026-01-21INSIDERAltman Peter bought 300 sh — Director, President and CEO ~$0k
    Showing the 40 most recent of 69 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage